Press coverage about Zogenix (NASDAQ:ZGNX) has been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Zogenix earned a media sentiment score of 0.13 on Accern’s scale. Accern also gave media stories about the company an impact score of 45.9593661569083 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Several equities analysts have commented on ZGNX shares. Mizuho started coverage on Zogenix in a research report on Wednesday, September 6th. They issued a “buy” rating and a $28.00 price objective on the stock. ValuEngine downgraded Zogenix from a “hold” rating to a “sell” rating in a research report on Friday, September 1st. Stifel Nicolaus reaffirmed a “buy” rating and issued a $55.00 price objective (up previously from $26.00) on shares of Zogenix in a research report on Friday, September 29th. Zacks Investment Research raised Zogenix from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. Finally, BidaskClub downgraded Zogenix from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 19th. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Zogenix presently has an average rating of “Buy” and an average target price of $40.00.

Zogenix (NASDAQ:ZGNX) opened at $41.10 on Monday. Zogenix has a 12-month low of $7.60 and a 12-month high of $42.50. The company has a current ratio of 3.59, a quick ratio of 3.48 and a debt-to-equity ratio of 0.20.

Zogenix (NASDAQ:ZGNX) last posted its quarterly earnings results on Tuesday, August 8th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.01). Zogenix had a negative return on equity of 70.75% and a negative net margin of 309.76%. The firm had revenue of $7.10 million for the quarter, compared to the consensus estimate of $3.48 million. During the same period in the previous year, the company posted ($0.76) EPS. Zogenix’s quarterly revenue was up 238.1% compared to the same quarter last year. sell-side analysts anticipate that Zogenix will post -3.64 earnings per share for the current year.

In related news, major shareholder Life Sciences Maste Perceptive acquired 300,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 3rd. The stock was purchased at an average cost of $37.50 per share, for a total transaction of $11,250,000.00. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. 6.60% of the stock is currently owned by corporate insiders.

TRADEMARK VIOLATION NOTICE: “Zogenix (ZGNX) Receives Daily News Impact Score of 0.13” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another website, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at

Zogenix Company Profile

Zogenix, Inc is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome.

Insider Buying and Selling by Quarter for Zogenix (NASDAQ:ZGNX)

Receive News & Stock Ratings for Zogenix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix Inc. and related stocks with our FREE daily email newsletter.